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Background: The aim of the study was to elucidate whether leukotriene receptor antagonists (LTRAs) can prevent
severe allergic reactions, which occur during oral immunotherapy (OIT) in children with food allergies.
Findings: Five children with food allergies [3 allergic to hen’s egg (HE), 1 to wheat, and one to cow’s milk (CM);
aged between 7 and 12 years; median, 8.5 years] who were started on LTRAs during OIT were retrospectively
selected from among 63 children undergoing OIT. In the rush phase, after the administration of the initial dose
which was set in open food challenge test, the subsequent doses were increased by approximately 1.2 times of the
previous dose and were administered every 2 hours, 4 times a day. The target doses of hen’s egg, wheat (udon
noodle), and cow’s milk in the rush phase were 50 g, 200 g, and 200 ml, respectively. The ingestion of the target
dose was continued at home every day for at least a year in the maintained phase.
Four participants experienced intractable abdominal pain during the rush phase; therefore, the loading dose was
not increased in these children. However, the administration of LTRAs prevented their symptoms, resulting in the
completion of the rush phase. One participant also experienced intractable abdominal pain during the
maintenance phase. After receiving LTRAs, the target dose was able to tolerated.
Conclusion: The findings from this retrospective study suggest that the administration of LTRAs is useful for the
prevention of adverse allergic reactions such as abdominal pain during OIT.
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Food allergy is defined as an adverse response to a spe-
cific food antigen that is initiated by the immune sys-
tem. The only current treatment for food allergy is
avoidance, while maintaining the hope of outgrowing
it over time. Although some trials of oral immuno-
therapy (OIT) in patients with food allergy have been
carried out, the rate of tolerance induction remains
uncertain, and food-induced allergic symptoms fre-
quently occur [1].
Eosinophilic gastroenteritis (EG) has been strongly
associated with food allergy, and concomitant atopic
disease or a family history of allergy is elicited in about
70% of cases [2].* Correspondence: taniuchi@takii.kmu.ac.jp
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stated.Leukotriene receptor antagonists (LTRAs) alleviate the
symptoms of many allergic diseases, including respiratory
symptoms such as bronchial asthma [3] and abdominal
symptoms such as those occurring during EG [4].
During OIT, patients are sometimes not able to con-
tinue the therapy due to severe allergic symptoms, espe-
cially intractable abdominal pain, repeated vomiting, and
diarrhea. Antihistamines and LTRAs have preventive ef-
fects in urticaria and wheezing, respectively; however, an
optimal treatment for abdominal symptoms that occur
during OIT has not been established.
In the present study, we described the cases of 5 children
who successfully continued OIT after the introduction
of LTRAs.
A retrospective survey of the medical records of 63
children who underwent OIT between 2010 and 2011
at Kansai Medical University was performed. Children
who received LTRAs from the start of OIT were excludedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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5 children with food allergies [3 allergic to hen’s egg
(HE), 1 to wheat, and one to cow’s milk (CM)] who
were started on LTRAs during OIT, these patients
were enrolled in the study.
The OIT was performed according to Itoh’s protocol
[5]. Before OIT, a double-blind, placebo control food
challenge was performed, and all five participants had
positive challenges. All five were hospitalized during the
rush phase of OIT as per protocol. The target doses of
HE, wheat (noodles), and CM in the rush phase were
50 g, 200 g, and 200 ml, respectively. Ingestion of the
target dose was continued at home every day to main-
tain the effect of OIT for at least 6–12 months in the
maintenance phase.
All study protocols were approved by the Institutional
Ethics Committee of Kansai Medical University.
Data for each of the five participants, who were
each started LTRAs during OIT, are summarized in
Table 1. All five developed severe abdominal pain
and were unable to continue OIT before receiving
LTRAs. The clinical course of each participant is
summarized below.
Case 1: HE allergic
OIT was initiated at 0.001 g of cooked egg. Repeated,
severe abdominal symptoms frequently are redundant
during the rush phase; therefore, the dose of egg
could not be increased. It remained 1.5 g at 27 days
after initiation of OIT. After administration of LTRAs,
severe abdominal symptoms no longer occurred with
any frequency, and the target dose was achieved after
22 days.
Case 2: HE allergic
OIT was initiated at 1.0 g of cooked egg. The dose in-
creased to 8.6 g with no severe adverse reactions for





Study phase at the start of LTRAs administration Ru
Frequencies/dose of AS before administration of LTRAs 0.4
Duration (days) of persistent AS before administration of LTRAs 6
Specific IgE level (UA/mL) before administration of LTRAs 25
Specific IgE level (UA/mL) after administration of LTRAs 19
Treatment period (months) of LTRAs 5
LTRAs: leukotriene receptor antagonisits.
M.P.: maintenance phase.
AS: abdominal symptoms.could not proceed due to repeated, severe abdominal
symptoms. After administration of LTRAs, abdominal
symptoms resolved completely, and the target dose
could be tolerated six days later.
Case 3: HE allergic
OIT was initiated at 0.001 g of cooked egg. The dose in-
creased to 2.6 g with no severe adverse allergic reaction
for 15 days. However, for the following five days, OIT
could not proceed due to repeated, severe abdominal
symptoms. Although the patient subsequently experi-
enced mild abdominal symptoms once, the target dose
was well-tolerated 5 days after the administration of
LTRAs.
Case 4: wheat allergic
OIT was initiated at 0.6 g of udon noodle. The dose in-
creased to 3.1 g with no severe adverse allergic reaction
for four days. However, for the following three days,
OIT could not proceed due to repeated, severe abdom-
inal symptoms. Although the patient subsequently ex-
perienced mild abdominal symptoms twice, the target
dose was well-tolerated 10 days after the administration
of LTRAs.
Case 5: CM allergic
During the rush phase of OIT, the participant experi-
enced no severe side effects and the target dose was
ultimately reached for 11 days. However, 49 days after
the end of the rush phase, the dose was decreased to
10 ml due to intractable abdominal pain and diarrhea.
These symptoms resolved completely after LTRAs ad-
ministration, and, by gradually increasing the dose by
1 ml each day, the target dose was tolerated for seven
months, even though intractable abdominal pain was
experienced three times and diarrhea twice during this
time.2 3 4 5
8 12 8 7
M M M F
g Egg Egg Wheat Cow’s milk
sh Rush Rush Rush M. P.
7 0.57 0.29 0.50 0.93
4 5 4 7
.1 12.7 9.61 78.1 0.90
.7 12.0 7.86 52.2 0.73
6 2 5 5
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dose without severe allergic abdominal symptoms after
the introduction of LTRAs. Finally, more than one year
after the start of OIT, they were able to maintain the target
dose of each food without the need for LTRAs.
In the OIT literature, food-induced allergic symptoms
are reportedly seen in 50-60% of cases [6,7]. Longo et al.
[8] also reported that 23 of 30 children with CM allergy in
their OIT group experienced food-induced allergic abdom-
inal symptoms.
LTRAs are used to treat the abdominal symptoms of
EG. Although the occurrence of EG is generally very low,
it frequently develops during OIT. However, to the best of
our knowledge, the effectiveness of LTRAs for food-
induced allergic abdominal symptoms has yet to be re-
ported. In the present study, we focused on the efficacy of
LTRAs for severe food-induced allergic abdominal symp-
toms during OIT, which was often interrupted because of
these symptoms. All participants were given LTRAs, and
OIT was subsequently tolerated; all achieved the target
dose and maintained OIT. This result suggests that LTRA
controls food-induced severe allergic abdominal symp-
toms. The mechanism of LTRA efficacy during OIT may
be explained by the inhibition of eosinophilic activation
[9] and degranulation of mast cells, both of which are
triggered by leukotriene [10].
Four studies have reported the occurrence of eosino-
philic esophagitis (EE) during OIT [11-14]. However only
one study showed that the causative food directly induces
EE during OIT for the children with CM allergy, and the
frequency of EE during OIT is 2.72% (3 out of 110 pa-
tients) [14]. In the present study, EE was not observed in
the 63 patients [24 allergic to hen’s egg (HE), 12 to wheat,
and 27 to cow’s milk (CM)] receiving OIT; the patients did
not show typical symptoms of EE such as general weak-
ness, low physical activity, sleep disturbance, and slow
growth, retrosternal pain, dysphagia, and abdominal pain
immediately after the ingestion of causative food. And also
10 out of the 63 patients had already received LTRA be-
cause of the treatment for persistent asthma. The diffe-
rence may be because of the preventive effect of LTRAs in
the development of EE or different causative food; thus,
LTRAs are effective in the treatment of EE [15].
Although a larger, double-blind, placebo controlled study
is needed to confirm the current results, we suggest that
LTRA may prove to be therapeutically efficacious for
treatment of food-induced severe allergic abdominal
symptoms during OIT.
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